ZENV
Zenvia Inc.
No data for this timeframe.
Vol
SEC Reports2
Recent Activity
Mar 19, 2026
SEC
Zenvia Inc. (ZENV) has filed Form 15 to terminate the registration of its Class A common shares under Section 12(g) of t
15-12G — Impact 7/10
Mar 12, 2026
SEC
Zenvia Inc. has filed an EFFECT notice, indicating that a previously filed registration statement has become effective,
EFFECT — Impact 4/10
Analyst Ratings
0Strong Buy
0Buy
3Hold
1Sell
2Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 13, 2023 | UBS | DOWNGRADE | Buy → Neutral |
| Sep 6, 2022 | Goldman Sachs | MAINTAIN | Neutral |
| Jul 8, 2022 | Morgan Stanley | DOWNGRADE | Overweight → Equal-Weight |
| Jul 5, 2022 | Goldman Sachs | DOWNGRADE | Buy → Neutral |
| Jan 19, 2022 | Goldman Sachs | MAINTAIN | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Next FY | $0.35 ▼ -19.4% | $0.35 — $0.35 | 86% YoY | 1 |
| Current Q | $-0.13 ▼ -1026.7% | $-0.13 — $-0.13 | 87% YoY | 1 |
| Next Q | $0.21 ▲ +952.4% | $0.21 — $0.21 | 165% YoY | 1 |
| Current FY | $0.19 ▲ +28.1% | $0.19 — $0.19 | 106% YoY | 1 |
Latest Reports
BEARISH
15-12G
7/10
Zenvia Inc. (ZENV) has filed Form 15 to terminate the registration of its Class A common shares under Section 12(g) of t
Mar 19, 2026
NEUTRAL
EFFECT
4/10
Zenvia Inc. has filed an EFFECT notice, indicating that a previously filed registration statement has become effective,
Mar 12, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 5.5/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Feb 2023): 0% buy across 6 analysts — 0 strong buy, 0 buy, 3 hold, 1 sell, 2 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Next FY 2026-12-31 |
$0.35 | $0.35 | $0.35 | 86.3% | -19.4% | — | $0.0B | — | 1 |
| Current Q 2025-03-31 |
$-0.13 | $-0.13 | $-0.13 | 86.6% | -1026.7% | — | $0.2B | 0.3% | 1 |
| Next Q 2025-06-30 |
$0.21 | $0.21 | $0.21 | 165.1% | +952.4% | — | $0.3B | 10.5% | 1 |
| Current FY 2025-12-31 |
$0.19 | $0.19 | $0.19 | 106.1% | +28.1% | — | $0.0B | — | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.126 | |
| 7d ago | $-0.126 | |
| 30d ago | $0.014 | -0.140 |
| 60d ago | $0.014 | -0.140 |
| 90d ago | $0.014 | -0.140 |
4 analyst firms have rated this stock: 0 upgrades, 3 downgrades, 2 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 13, 2023 | UBS | DOWNGRADE | Buy | Neutral |
| Sep 6, 2022 | Goldman Sachs | MAINTAIN | — | Neutral |
| Jul 8, 2022 | Morgan Stanley | DOWNGRADE | Overweight | Equal-Weight |
| Jul 5, 2022 | Goldman Sachs | DOWNGRADE | Buy | Neutral |
| Jan 19, 2022 | Goldman Sachs | MAINTAIN | — | Buy |
| Aug 23, 2021 | Itau BBA | INITIATE | — | Outperform |
| Aug 16, 2021 | Goldman Sachs | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| May 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Apr 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Mar 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Feb 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Jan 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.